Renowned Neurologist Dr. Serge Gauthier to Serve as Site’s Lead Investigator

For more information please contact:


Stephen Kilmer

Investor Relations 

(514) 331-7440 ext 232

stephen@intelgenx.com

Or

Andre Godin, CPA, CA

Executive Vice-President and CFO

IntelGenx Corp.

(514) 331-7440 ext 203

andre@intelgenx.com

SAINT LAURENT, Quebec, Feb. 11, 2019 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSX-V:IGX) (OTCQX:IGXT) (“IntelGenx”), a leading oral drug delivery company, today announced that it has received a Decision to Grant notice from the Japanese Patent Office (JPO) to issue a patent entitled “Instantly wettable oral film dosage form without surfactant or polyalcohol.”

Once the JPO’s administrative process is complete, the patent that issues from this application will provide intellectual property protection in Japan for the formulation of IntelGenx’ VersaFilm™ technology used in its RIZAPORT^® product, through 2034. RIZAPORT^® is an oral thin film formulation of rizatriptan benzoate for the treatment of acute migraines. The Decision to Grant notice is the final approval stage and precedes actual granting, which is expected shortly. The identification number is Japanese Patent Application 2016-530631. IntelGenx received a similar formulation patent covering its RIZAPORT^® VersaFilm™ technology from the European Patent Office in 2018 and from the United States Patent and Trademark Office in 2016, and has additional applications pending in other countries.

“This allowance adds to the formidable intellectual property estate that we are building for RIZAPORT^® around the globe,” said Dr. Horst G. Zerbe, President and CEO of IntelGenx. “Japan is the world’s third-largest pharmaceuticals market and, as such, represents a significant commercial opportunity for RIZAPORT^®.  Moving forward, we will be actively seeking a marketing partner for the product in this jurisdiction.”

About RIZAPORT^®:

RIZAPORT^® is a patent protected proprietary oral thin film formulation of rizatriptan benzoate, a 5-HT1 receptor agonist and the active drug in Merck & Co.'s Maxalt^®.

Rizatriptan is considered to be one of the most effective oral triptans, a class of molecules that constricts blood vessels in the brain to relieve swelling and other migraine symptoms. RIZAPORT^® is based on IntelGenx’ proprietary VersaFilm™ technology.  It dissolves rapidly and releases its active ingredient in the mouth.  The administration method of the RIZAPORT^® oral soluble film, which does not require the patient to swallow a pill or consume water, along with its neutral flavor, presents a potentially attractive therapeutic alternative for migraine patients, specifically for patients who suffer from migraine-related nausea, estimated to be approximately 80% of the total migraine patient population and patients suffering from dysphagia (difficulty swallowing)¹.

Reference:

¹ Lipton RB, Buse DC, Saiers J, Fanning KM, Serrano D, Reed ML. (2013) Frequency and burden of headache-related nausea: results from the American Migraine Prevalence and Prevention (AMPP) study, Headache. 2013 Jan;53(1):93-103.

About IntelGenx

Established in 2003, IntelGenx is a leading oral drug delivery company primarily focused on the development and manufacturing of innovative pharmaceutical oral films based on its proprietary VersaFilm™ technology platform.

IntelGenx's highly skilled team provides comprehensive pharmaceuticals services to pharmaceutical partners, including R&D, analytical method development, clinical monitoring, IP and regulatory services. IntelGenx's state-of-the-art manufacturing facility, which was established for the VersaFilm™ technology platform, offers by supporting lab-scale to pilot- and commercial-scale production. More information about the company can be found at www.intelgenx.com.

Forward Looking Statements

This document may contain forward-looking information about IntelGenx' operating results and business prospects that involve substantial risks and uncertainties. Statements that are not purely historical are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. These statements include, but are not limited to, statements about IntelGenx' plans, objectives, expectations, strategies, intentions or other characterizations of future events or circumstances and are generally identified by the words "may," "expects," "anticipates," "intends," "plans," "believes," "seeks," "estimates," "could," "would," and similar expressions. All forward looking statements are expressly qualified in their entirety by this cautionary statement. Because these forward-looking statements are subject to a number of risks and uncertainties, IntelGenx's actual results could differ materially from those expressed or implied by these forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those discussed under the heading "Risk Factors" in IntelGenx's annual report on Form 10-K, filed with the United States Securities and Exchange Commission and available at www.sec.gov, and also filed with Canadian securities regulatory authorities at www.sedar.com. IntelGenx assumes no obligation to update any such forward-looking statements.

Each of the TSX Venture Exchange and OTCQX has neither approved nor disapproved the contents of this press release.  Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Source:  IntelGenx Technologies Corp.

For more information, please contact:


Stephen Kilmer

Investor Relations 

(514) 331-7440 ext 232

stephen@intelgenx.com

Or

Andre Godin, CPA, CA

Executive Vice-President and CFO

IntelGenx Corp.

(514) 331-7440 ext 203

andre@intelgenx.com

SAINT LAURENT, Quebec, Jan. 30, 2019 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSX-V:IGX) (OTCQX:IGXT) (“IntelGenx”), a leading oral drug delivery company, today announced that the U.S. Food and Drug Administration (“FDA”) has performed a Pre-Approval Inspection (“PAI”) of the company’s Health Canada-certified cGMP manufacturing facility in Montreal. The PAI is related to the IntelGenx New Drug Application (“NDA”) for RIZAPORT^®, a VersaFilm™ oral soluble film for the treatment of acute migraines. At the conclusion of the PAI on January 25, the FDA issued a Form 483 with five inspectional observations.

“We appreciate the thoroughness of the FDA’s review of our facility, and we are confident that we will be able to address the FDA’s observations within the 15-day response timeframe,” said Dr. Horst G. Zerbe, President and CEO of IntelGenx. “As we continue to advance through the NDA process, IntelGenx is excited to have completed another important milestone toward U.S. approval.”

The FDA has assigned a Prescription Drug User Fee Act goal date of April 1, 2019, for completion of the review of the resubmitted NDA for RIZAPORT^®. IntelGenx does not expect the inspectional observations to impact the timeline for the FDA’s decision on the approval of RIZAPORT^®.

In December 2018, IntelGenx entered into a definitive licensing, development and supply agreement granting Gensco^® Pharma the exclusive right to commercialize the IntelGenx RIZAPORT^® product in the United States.

About RIZAPORT^®:

RIZAPORT^® is a patent protected proprietary oral thin film formulation of rizatriptan benzoate, a 5-HT1 receptor agonist and the active drug in Merck & Co.'s Maxalt^®.

Rizatriptan is considered to be one of the most effective oral triptans, a class of molecules that constricts blood vessels in the brain to relieve swelling and other migraine symptoms. RIZAPORT^® is based on IntelGenx’s proprietary VersaFilm™ technology. It dissolves rapidly and releases its active ingredient in the mouth. The administration method of the RIZAPORT^® oral soluble film, which does not require the patient to swallow a pill or consume water, along with its neutral flavor, presents a potentially attractive therapeutic alternative for migraine patients, specifically for patients who suffer from migraine-related nausea, estimated to be approximately 80% of the total migraine patient population and patients suffering from dysphagia (difficulty swallowing)¹.

References:

¹ Lipton RB, Buse DC, Saiers J, Fanning KM, Serrano D, Reed ML. (2013) Frequency and burden of headache-related nausea: results from the American Migraine Prevalence and Prevention (AMPP) study, Headache. 2013 Jan;53(1):93-103.

About IntelGenx

Established in 2003, IntelGenx is a leading oral drug delivery company primarily focused on the development and manufacturing of innovative pharmaceutical oral films based on its proprietary VersaFilm™ technology platform.

IntelGenx's highly skilled team provides comprehensive pharmaceuticals services to pharmaceutical partners, including R&D, analytical method development, clinical monitoring, IP and regulatory services. IntelGenx's state-of-the-art manufacturing facility, which was established for the VersaFilm™ technology platform, offers by supporting lab-scale to pilot- and commercial-scale production. More information about the company can be found at www.intelgenx.com.

Forward Looking Statements

This document may contain forward-looking information about IntelGenx's operating results and business prospects that involve substantial risks and uncertainties. Statements that are not purely historical are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. These statements include, but are not limited to, statements about IntelGenx's plans, objectives, expectations, strategies, intentions or other characterizations of future events or circumstances and are generally identified by the words "may," "expects," "anticipates," "intends," "plans," "believes," "seeks," "estimates," "could," "would," and similar expressions. All forward looking statements are expressly qualified in their entirety by this cautionary statement. Because these forward-looking statements are subject to a number of risks and uncertainties, IntelGenx's actual results could differ materially from those expressed or implied by these forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those discussed under the heading "Risk Factors" in IntelGenx's annual report on Form 10-K, filed with the United States Securities and Exchange Commission and available at www.sec.gov, and also filed with Canadian securities regulatory authorities at www.sedar.com. IntelGenx assumes no obligation to update any such forward-looking statements.

Each of the TSX Venture Exchange and OTCQX has neither approved nor disapproved the contents of this press release.  Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Source:  IntelGenx Technologies Corp.

For more information please contact: Stephen Kilmer Investor Relations (514) 331-7440 ext 232 stephen@intelgenx.com   Or Andre Godin, CPA, CA Executive Vice-President and CFO IntelGenx Corp. (514) 331-7440 ext 203 andre@intelgenx.com 

Eight Alzheimer’s Disease Patients Randomized to Date with Two Additional Sites Expected

SAINT LAURENT, Quebec, Jan. 23, 2019 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSX-V:IGX) (OTCQX:IGXT) (“IntelGenx”), a leading oral drug delivery company, today provided an update on its Phase 2a study of Montelukast VersaFilm™ in patients with mild to moderate Alzheimer’s Disease (AD).

To date, seven study sites across Canada have randomized eight subjects, many of which commenced dosing in late-2018. IntelGenx sponsored study sites are actively screening for new patients and IntelGenx expects enrollment to accelerate following the holiday season hiatus. In addition to opening its planned eighth trial site, IntelGenx is preparing to open an additional site in Montreal, bringing the total number of sites to nine.

“We are looking forward to commencing patient recruitment at our eighth site in the coming weeks, as well as opening an additional site in Montreal by the end of first quarter 2019,” said Dr. Horst G. Zerbe, President and CEO of IntelGenx. “Although in its early stages, this is an exciting trial for IntelGenx as we work with our study sites to achieve a shared goal of finding a treatment that benefits patients living with this most unfortunate and debilitating disease.”

“Unlike traditional dosage forms, our Montelukast VersaFilm™ is engineered to deliver Montelukast with an improved bioavailability, which may be more efficacious than known Montelukast dosage forms in crossing the blood-brain barrier,” contends Dr. Zerbe.  “As a result, our VersaFilm™ technology has the potential to be broadly applicable to a wide variety of other pharmaceutical treatment options.”

The randomized, double-blind, placebo-controlled Phase 2a “proof of concept” study will enroll approximately 70 subjects with mild to moderate AD. The study will evaluate the safety, feasibility, tolerability, and efficacy of Montelukast buccal film following daily dosing for 26 weeks.

About Montelukast VersaFilm™

Montelukast is a leukotriene receptor antagonist that was approved by the U.S. Food and Drug Administration in 1997 for the treatment of asthma and seasonal allergic rhinitis. IntelGenx is working to repurpose Montelukast as a therapeutic to treat neurodegenerative diseases by re-formulating the drug into an oral film-based product. IntelGenx's proprietary VersaFilm™ technology is especially suited for special needs patient populations, and the Montelukast VersaFilm™ product offers many distinct advantages over tablets for Alzheimer’s Disease patients, including the avoidance and minimization of first-pass-effects, ease of administration, improved API bioavailability, lower dosing and toxicity, better acceptability and improved compliance.

In a recent Phase 1 study, IntelGenx demonstrated that an oral film formulation of Montelukast is safe and tolerable in healthy subjects, reduces the first-pass-effect and has a 52% higher bioavailability compared to the regular Montelukast tablet, demonstrating a clear advantage of delivering Montelukast via film. IntelGenx's oral film also crossed the blood-brain barrier, an essential feature for treating degenerative brain diseases.

About IntelGenx

Established in 2003, IntelGenx is a leading oral drug delivery company primarily focused on the development and manufacturing of innovative pharmaceutical oral films based on its proprietary VersaFilm™ technology platform.

IntelGenx's highly skilled team provides comprehensive pharmaceuticals services to pharmaceutical partners, including R&D, analytical method development, clinical monitoring, IP and regulatory services. IntelGenx's state-of-the-art manufacturing facility, which was established for the VersaFilm™ technology platform, offers by supporting lab-scale to pilot- and commercial-scale production. More information about the company can be found at www.intelgenx.com.

Forward Looking Statements

This document may contain forward-looking information about IntelGenx's operating results and business prospects that involve substantial risks and uncertainties. Statements that are not purely historical are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. These statements include, but are not limited to, statements about IntelGenx's plans, objectives, expectations, strategies, intentions or other characterizations of future events or circumstances and are generally identified by the words "may," "expects," "anticipates," "intends," "plans," "believes," "seeks," "estimates," "could," "would," and similar expressions. All forward looking statements are expressly qualified in their entirety by this cautionary statement. Because these forward-looking statements are subject to a number of risks and uncertainties, IntelGenx's actual results could differ materially from those expressed or implied by these forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those discussed under the heading "Risk Factors" in IntelGenx's annual report on Form 10-K, filed with the United States Securities and Exchange Commission and available at www.sec.gov, and also filed with Canadian securities regulatory authorities at www.sedar.com. IntelGenx assumes no obligation to update any such forward-looking statements.

Each of the TSX Venture Exchange and OTCQX has neither approved nor disapproved the contents of this press release.  Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Source:  IntelGenx Technologies Corp.

For more information please contact:


Stephen Kilmer

Investor Relations 

(514) 331-7440 ext 232

stephen@intelgenx.com

Or

Andre Godin, CPA, CA

Executive Vice-President and CFO

IntelGenx Corp.

(514) 331-7440 ext 203

andre@intelgenx.com

Working with partner Tilray^®, IntelGenx aims to launch oral film products in late-2019

SAINT LAURENT, Quebec, Jan. 14, 2019 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSX-V:IGX) (OTCQX:IGXT) (“IntelGenx”), a leading oral drug delivery company, today provided an update on its cannabis-infused VersaFilm^TM product co-development program with Tilray, Inc. (NASDAQ:TLRY) (“Tilray®”) following the Government of Canada’s recently proposed amendments to the Cannabis Act (the “Act”) that would authorize the sale of edible cannabis products.

“We are pleased with the timeliness of the Canadian Government’s proposed amendments to the Act and we will be participating in the public consultation process,” said Dr. Horst G. Zerbe, President and CEO of IntelGenx.

“In addition to having the only Health Canada licensed and GMP compliant facility for pharmaceutical oral film manufacturing, IntelGenx has the competitive advantage of having Tilray^®, a global leader in cannabis production and distribution, as both a partner and a shareholder,” continued Dr. Zerbe. “Together, we will work to develop a cannabis-infused oral film that complies with the proposed, and subsequently, the final amendments to the Act such that we are ready for commercialization shortly after the October 17, 2019 implementation deadline.”

Under the terms of the development and supply agreement IntelGenx entered into with Tilray in November 2018, the companies will co-develop and commercialize oral film products infused with adult-use and medical cannabis. As the amended cannabis regulations, which are expected to come into effect no later than October 17, 2019, would allow adult-use consumers to purchase edible products in Canada, IntelGenx and Tilray^® are working toward commercializing a cannabis-infused VersaFilm™ product in late-2019.

About IntelGenx

Established in 2003, IntelGenx is a leading oral drug delivery company primarily focused on the development and manufacturing of innovative pharmaceutical oral films based on its proprietary VersaFilm™ technology platform.

IntelGenx' highly skilled team provides comprehensive pharmaceuticals services to pharmaceutical partners, including R&D, analytical method development, clinical monitoring, IP and regulatory services. IntelGenx' state-of-the-art manufacturing facility, which was established for the VersaFilm™ technology platform, offers by supporting lab-scale to pilot- and commercial-scale production. More information about the company can be found at www.intelgenx.com.

Forward Looking Statements:

This document may contain forward-looking information about IntelGenx' operating results and business prospects that involve substantial risks and uncertainties. Statements that are not purely historical are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. These statements include, but are not limited to, statements about IntelGenx' plans, objectives, expectations, strategies, intentions or other characterizations of future events or circumstances and are generally identified by the words "may," "expects," "anticipates," "intends," "plans," "believes," "seeks," "estimates," "could," "would," and similar expressions. All forward looking statements are expressly qualified in their entirety by this cautionary statement. Because these forward-looking statements are subject to a number of risks and uncertainties, IntelGenx' actual results could differ materially from those expressed or implied by these forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those discussed under the heading "Risk Factors" in IntelGenx' annual report on Form 10-K, filed with the United States Securities and Exchange Commission and available at www.sec.gov, and also filed with Canadian securities regulatory authorities at www.sedar.com. IntelGenx assumes no obligation to update any such forward-looking statements.

Each of the TSX Venture Exchange and OTCQX has neither approved nor disapproved the contents of this press release.  Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Source:  IntelGenx Technologies Corp.

For IntelGenx:


Stephen Kilmer

Investor Relations 

(514) 331-7440 ext 232

stephen@intelgenx.com

Or

Andre Godin, CPA, CA

Executive Vice-President and CFO

IntelGenx Corp.

(514) 331-7440 ext 203

andre@intelgenx.com

SAINT LAURENT, Quebec, Dec. 12, 2018 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSX-V: IGX) (OTCQX: IGXT) (“IntelGenx”), a leading oral drug delivery company, today announced the execution of a definitive licensing, development and supply agreement (the “Agreement”) with Gensco^®Pharma (Gensco^®), a specialty pharmaceutical company focusing on research, development and marketing of prescription products, for the exclusive commercialization of RIZAPORT^® in the United States.

Upon the anticipated RIZAPORT^® approval by the US Food and Drug Administration (“FDA”), the product will become the first oral thin film on the market for the treatment of migraines, and will also be the first commercialized film product developed and manufactured at IntelGenx’s state-of-the-art facilities.

“We believe this exciting partnership with Gensco^® offers a tremendous opportunity to commercialize RIZAPORT^® in the world’s largest migraine market¹,” said Dr. Horst Zerbe, CEO of IntelGenx. “We are pleased to work with Gensco^® and its seasoned team of industry veterans with proven track records of launching and commercializing important therapies using innovative drug delivery systems.”

“The Gensco^® Pharma team is eager to launch RIZAPORT^® as a new therapeutic option for the benefit of patients suffering from migraines.  This innovative therapy aligns with Gensco^®’s mission to provide patients with unique delivery systems to effectively and safely manage their pain.  We look forward to partnering with the IntelGenx team and executing a highly successful RIZAPORT^® commercial launch,” commented Carlos Alfaras, President and CEO of Gensco^®.

Under the Agreement, Gensco^® has been granted the exclusive right to commercialize the IntelGenx RIZAPORT^® product in the United States.  In return, IntelGenx is entitled to receive royalty payments based on net profits of RIZAPORT^®.  IntelGenx is also eligible to receive milestone payments upon FDA approval and product launch. The agreement also gives Gensco^® exclusivity to develop the market, sell, distribute and fully commercialize products as a IntelGenx partner for the People’s Republic of China.

About RIZAPORT^®:

RIZAPORT^® is a patent protected proprietary oral thin film formulation of rizatriptan benzoate, a 5-HT1 receptor agonist and the active drug in Merck & Co.'s Maxalt^®.

Rizatriptan is considered to be one of the most effective oral triptans, a class of molecules that constricts blood vessels in the brain to relieve swelling and other migraine symptoms. RIZAPORT^® is based on IntelGenx’s proprietary VersaFilm™ technology.  It dissolves rapidly and releases its active ingredient in the mouth.  The administration method of the RIZAPORT^® oral soluble film, which does not require the patient to swallow a pill or consume water, along with its neutral flavor, presents a potentially attractive therapeutic alternative for migraine patients, specifically for patients who suffer from migraine-related nausea, estimated to be approximately 80% of the total migraine patient population and patients suffering from dysphagia (difficulty swallowing)².

The FDA has assigned a Prescription Drug User Fee Act (PDUFA) goal date of April 1, 2019, for completion of the review of the resubmitted New Drug Application for RIZAPORT^®.

References:

¹ www.globaldata.com/global-migraine-market-set-to-be-worth-8-7-billion-by-2026-2/ 

² Lipton RB, Buse DC, Saiers J, Fanning KM, Serrano D, Reed ML. (2013) Frequency and burden of headache-related nausea: results from the American Migraine Prevalence and Prevention (AMPP) study, Headache. 2013 Jan;53(1):93-103.

About Gensco^® Pharma:

Gensco^® is a specialty pharmaceutical manufacturer specializing in development and commercialization of prescription transdermal products. Gensco^®’s capabilities allow for the quick launch of products into significant niche markets. 

Resources are focused on innovative research, the development of superior quality medications and unique delivery systems. Gensco^® is an evidence-based solutions company that is progressively developing products utilizing new technologies that deliver outcomes to reduce the effects caused by disease or pathology.  More information about Gensco^® can be found at https://genscopharma.com/.

About IntelGenx:

Established in 2003, IntelGenx is a leading oral drug delivery company primarily focused on the development and manufacturing of innovative pharmaceutical oral films based on its proprietary VersaFilm™ technology platform.

IntelGenx's highly skilled team provides comprehensive pharmaceuticals services to pharmaceutical partners, including R&D, analytical method development, clinical monitoring, IP and regulatory services.  IntelGenx's state-of-the-art manufacturing facility, established for the VersaFilm™ technology platform, supports lab-scale to pilot and commercial-scale production, offering full service capabilities to its clients.  More information about IntelGenx can be found at www.intelgenx.com.

Forward Looking Statements:

This document may contain forward-looking information about IntelGenx's operating results and business prospects that involve substantial risks and uncertainties. Statements that are not purely historical are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. These statements include, but are not limited to, statements about IntelGenx's plans, objectives, expectations, strategies, intentions or other characterizations of future events or circumstances and are generally identified by the words "may," "expects," "anticipates," "intends," "plans," "believes," "seeks," "estimates," "could," "would," and similar expressions.  All forward looking statements are expressly qualified in their entirety by this cautionary statement. Because these forward-looking statements are subject to a number of risks and uncertainties, IntelGenx's actual results could differ materially from those expressed or implied by these forward-looking statements.  Factors that could cause or contribute to such differences include, but are not limited to, those discussed under the heading "Risk Factors" in IntelGenx's annual report on Form 10-K, filed with the United States Securities and Exchange Commission and available at www.sec.gov, and also filed with Canadian securities regulatory authorities at www.sedar.com. IntelGenx assumes no obligation to update any such forward-looking statements.

Each of the TSX Venture Exchange and OTCQX has neither approved nor disapproved the contents of this press release.  Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Source:  IntelGenx Technologies Corp.

For more information, please contact:


Stephen Kilmer

Investor Relations 

(514) 331-7440 ext 232

stephen@intelgenx.com

Or

Andre Godin, CPA, CA

Executive Vice-President and CFO

IntelGenx Corp.

(514) 331-7440 ext 203

andre@intelgenx.com

SAINT LAURENT, Quebec, Nov. 27, 2018 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSX-V: IGX) (OTCQX: IGXT) (the “Company” or “IntelGenx”) today announced that patient dosing has commenced in the Phase 2a study of Montelukast VersaFilm™ in patients with mild to moderate Alzheimer’s Disease (AD). The True North Clinical Research site in Kentville, Nova Scotia is the first of eight research sites in Canada to enrol a patient and commence dosing.

This randomized, double-blind, placebo controlled Phase 2a proof of concept study will enroll approximately 70 subjects with mild to moderate AD.  The study will evaluate the safety, feasibility, tolerability, and efficacy of Montelukast buccal film following daily dosing for 26 weeks.  Currently, seven of eight research sites have been activated and actively recruiting patients.

About Montelukast VersaFilm™:

Montelukast is a leukotriene receptor antagonist used for the maintenance treatment of asthma and to relieve symptoms of seasonal allergies. Montelukast is a CysLT1 antagonist; it blocks the action of leukotriene D4, a natural substance produced in the body involved in inflammation, (and secondary ligands LTC4 and LTE4) on the cysteinyl leukotriene receptor CysLT1 in the lungs and bronchial tubes by binding to it. This reduces the narrowing of bronchioles otherwise caused by the leukotriene and results in less inflammation. IntelGenx’s Montelukast buccal film offers a distinct dosage form that improves bioavailability and removes the need for water intake. The latest formulation successfully demonstrated enhanced bioavailability as compared with the brand tablet in a pilot study.

About IntelGenx:

Established in 2003, IntelGenx is a leading oral drug delivery company primarily focused on the development and manufacturing of innovative pharmaceutical oral films based on its proprietary VersaFilm™ technology platform.

IntelGenx's highly skilled team provides comprehensive pharmaceuticals services to pharmaceutical partners, including R&D, analytical method development, clinical monitoring, IP and regulatory services.  IntelGenx's state-of-the-art manufacturing facility, established for the VersaFilm™ technology platform, supports lab-scale to pilot and commercial-scale production, offering full service capabilities to its clients.  More information about the Company can be found at www.intelgenx.com.

Forward Looking Statements:

This document may contain forward-looking information about IntelGenx's operating results and business prospects that involve substantial risks and uncertainties. Statements that are not purely historical are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. These statements include, but are not limited to, statements about IntelGenx's plans, objectives, expectations, strategies, intentions or other characterizations of future events or circumstances and are generally identified by the words "may," "expects," "anticipates," "intends," "plans," "believes," "seeks," "estimates," "could," "would," and similar expressions.  All forward looking statements are expressly qualified in their entirety by this cautionary statement. Because these forward-looking statements are subject to a number of risks and uncertainties, IntelGenx's actual results could differ materially from those expressed or implied by these forward-looking statements.  Factors that could cause or contribute to such differences include, but are not limited to, those discussed under the heading "Risk Factors" in IntelGenx's annual report on Form 10-K, filed with the United States Securities and Exchange Commission and available at www.sec.gov, and also filed with Canadian securities regulatory authorities at www.sedar.com. IntelGenx assumes no obligation to update any such forward-looking statements.

Each of the TSX Venture Exchange and OTCQX has neither approved nor disapproved the contents of this press release.  Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Source:  IntelGenx Technologies Corp.

For more information, please contact:


Stephen Kilmer

Investor Relations 

(514) 331-7440 ext 232

stephen@intelgenx.com

Or

Andre Godin, CPA, CA

Executive Vice-President and CFO

IntelGenx Corp.

(514) 331-7440 ext 203

andre@intelgenx.com

- PDUFA Goal Date of April 1, 2019 -

SAINT LAURENT, Quebec, Nov. 20, 2018 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSX-V: IGX) (OTCQX: IGXT) (the “Company” or “IntelGenx”) today announced that its 505(b)(2) New Drug Application (“NDA”) resubmission for RIZAPORT^® oral soluble film 10 mg for the treatment of acute migraines has been accepted for review by the U.S. Food and Drug Administration (“FDA”).  The FDA has assigned a Prescription Drug User Fee Act (“PDUFA”) goal date for completion of the review of the RIZAPORT^® NDA of April 1, 2019.

“We are pleased that the FDA has accepted for review the resubmission of the NDA for RIZAPORT^®, and will be working with the Agency to achieve our goal of offering the first oral thin film on the market for the treatment of migraines,“ said Dr. Horst Zerbe, CEO of IntelGenx. 

About RIZAPORT^®:

RIZAPORT^® is a patent protected proprietary oral thin film formulation of rizatriptan benzoate, a 5-HT1 receptor agonist and the active drug in Merck & Co.'s Maxalt^®.  

Rizatriptan is considered to be one of the most effective oral triptans, a class of molecules that constricts blood vessels in the brain to relieve swelling and other migraine symptoms. RIZAPORT^® is based on IntelGenx’s proprietary VersaFilm™ technology.  It dissolves rapidly and releases its active ingredient in the mouth, leading to efficient absorption of the drug through the gastrointestinal tract.  The administration method of the RIZAPORT^® oral soluble film, which does not require the patient to swallow a pill or consume water, along with its neutral flavor, presents a potentially attractive therapeutic alternative for migraine patients, specifically for patients who suffer from migraine-related nausea, estimated to be approximately 80% of the total migraine patient population and patients suffering from dysphagia (difficulty swallowing)¹.

Reference:

¹ Lipton RB, Buse DC, Saiers J, Fanning KM, Serrano D, Reed ML. (2013) Frequency and burden of headache-related nausea: results from the American Migraine Prevalence and Prevention (AMPP) study, Headache. 2013 Jan;53(1):93-103.

About IntelGenx:

Established in 2003, IntelGenx is a leading oral drug delivery company primarily focused on the development and manufacturing of innovative pharmaceutical oral films based on its proprietary VersaFilm™ technology platform.

IntelGenx's highly skilled team provides comprehensive pharmaceuticals services to pharmaceutical partners, including R&D, analytical method development, clinical monitoring, IP and regulatory services.  IntelGenx's state-of-the-art manufacturing facility, established for the VersaFilm™ technology platform, supports lab-scale to pilot and commercial-scale production, offering full service capabilities to its clients.  More information about the Company can be found at www.intelgenx.com.

Forward Looking Statements:

This document may contain forward-looking information about IntelGenx's operating results and business prospects that involve substantial risks and uncertainties. Statements that are not purely historical are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. These statements include, but are not limited to, statements about IntelGenx's plans, objectives, expectations, strategies, intentions or other characterizations of future events or circumstances and are generally identified by the words "may," "expects," "anticipates," "intends," "plans," "believes," "seeks," "estimates," "could," "would," and similar expressions.  All forward looking statements are expressly qualified in their entirety by this cautionary statement. Because these forward-looking statements are subject to a number of risks and uncertainties, IntelGenx's actual results could differ materially from those expressed or implied by these forward-looking statements.  Factors that could cause or contribute to such differences include, but are not limited to, those discussed under the heading "Risk Factors" in IntelGenx's annual report on Form 10-K, filed with the United States Securities and Exchange Commission and available at www.sec.gov, and also filed with Canadian securities regulatory authorities at www.sedar.com. IntelGenx assumes no obligation to update any such forward-looking statements.

Each of the TSX Venture Exchange and OTCQX has neither approved nor disapproved the contents of this press release.  Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Source:  IntelGenx Technologies Corp.

For more information, please contact:

Stephen Kilmer
Investor Relations
(514) 331-7440 ext 232
stephen@intelgenx.com

Or

Andre Godin, CPA, CA
Executive Vice-President and CFO
IntelGenx Corp.
(514) 331-7440 ext 203
andre@intelgenx.com 

SAINT LAURENT, Quebec, Nov. 07, 2018 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSX-V:IGX) (OTCQX:IGXT) (“IntelGenx”), a leading oral drug delivery company, today announced the execution of a definitive license, development and supply agreement (the “Agreement”) with Tilray, Inc. (NASDAQ:TLRY) (“Tilray^®”), a global leader in cannabis production and distribution.  Pursuant to the Agreement, the two companies will co-develop and commercialize oral film products infused with adult-use and medical cannabis (“cannabis-infused VersaFilm™”), in anticipation of amended cannabis regulations that would allow adult-use consumers to purchase edible products in Canada. 

Under the Agreement, IntelGenx and Tilray^® will each fund 20% and 80% of the costs associated with the development of the cannabis-infused Versafilm™ products, respectively.  IntelGenx will have the exclusive right to manufacture and supply the co-developed products to Tilray^®, and will also receive a fixed single-digit royalty on net product sales.  Tilray^® will have the exclusive, worldwide marketing and distribution rights for the co-developed products.

In connection with the Agreement, the parties have also executed a subscription agreement pursuant to which Tilray^® will make a strategic investment in IntelGenx by way of a non-brokered private placement (“Private Placement”).  Pursuant to the Private Placement, Tilray^® will purchase 1,428,571 common shares of IntelGenx at a price of US$0.70 per share for gross proceeds to IntelGenx of US$1 million. The price of US$0.70 per share, rather than the US$0.80 per share price which had been proposed in the non-binding letter of intent between the parties and announced on September 20, 2018, represents the price per unit paid by investors under IntelGenx’s recent public offering.  IntelGenx intends to use the proceeds from the Private Placement for cannabis-infused VersaFilm™ product development in connection with the Agreement.  The Private Placement is expected to close on or about November 9, 2018, subject to approval by the TSX Venture Exchange and satisfaction of customary closing conditions.

“With IntelGenx having the only Health Canada compliant and licensed facility for pharmaceutical oral film manufacturing, we are excited to establish this important partnership with Tilray, a global leader in the medical and adult-use cannabis industry, and a company that shares our enthusiasm about the prospects for oral thin film delivery,” said Dr. Horst G. Zerbe, President and CEO of IntelGenx.  “Both companies see a world where innovative, pharmaceutical-grade cannabis products are made available to adult consumers and patients, and we are looking forward to working with Tilray to make that a reality.”

“Over the long-term, we believe a significant portion of the global cannabis market will be focused on non-combustible products,” said Woody Pastorius, Chief Revenue Officer of Tilray^®.  “Through this partnership, we look forward to co-developing oral film products infused with cannabis that we intend to market and distributed in Canada and other markets around the world as regulations permit.”

About IntelGenx

Established in 2003, IntelGenx is a leading oral drug delivery company primarily focused on the development and manufacturing of innovative pharmaceutical oral films based on its proprietary VersaFilm™ technology platform.

IntelGenx's highly skilled team provides comprehensive pharmaceuticals services to pharmaceutical partners, including R&D, analytical method development, clinical monitoring, IP and regulatory services. IntelGenx's state-of-the-art manufacturing facility, which was established for the VersaFilm™ technology platform, offers by supporting lab-scale to pilot- and commercial-scale production.  More information about the company can be found at www.intelgenx.com.

Forward Looking Statements:

This document may contain forward-looking information about IntelGenx's operating results and business prospects that involve substantial risks and uncertainties. Statements that are not purely historical are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended.  These statements include, but are not limited to, statements about IntelGenx's plans, objectives, expectations, strategies, intentions or other characterizations of future events or circumstances and are generally identified by the words "may," "expects," "anticipates," "intends," "plans," "believes," "seeks," "estimates," "could," "would," and similar expressions.  All forward looking statements are expressly qualified in their entirety by this cautionary statement.  Because these forward-looking statements are subject to a number of risks and uncertainties, IntelGenx's actual results could differ materially from those expressed or implied by these forward-looking statements.  Factors that could cause or contribute to such differences include, but are not limited to, those discussed under the heading "Risk Factors" in IntelGenx's annual report on Form 10-K, filed with the United States Securities and Exchange Commission and available at www.sec.gov, and also filed with Canadian securities regulatory authorities at www.sedar.com.  IntelGenx assumes no obligation to update any such forward-looking statements.

Each of the TSX Venture Exchange and OTCQX has neither approved nor disapproved the contents of this press release.  Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Source:  IntelGenx Technologies Corp.

For IntelGenx:

Stephen Kilmer
Investor Relations
(514) 331-7440 ext 232
stephen@intelgenx.com

Or

Andre Godin, CPA, CA
Executive Vice-President and CFO
IntelGenx Corp.
(514) 331-7440 ext 203
andre@intelgenx.com

For Tilray^®:

Media:
news@tilray.com
1 (833) 206-8161

Or

Investors:
Katie Turner
(646) 277-1228
katie.turner@icrinc.com

SAINT LAURENT, Quebec, Oct. 31, 2018 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSX-V: IGX) (OTCQX: IGXT) (the “Company” or “IntelGenx”) is pleased to announced that its commercialization partner for RIZAPORT® (10mg) in Spain, Groupo Juste, which is now part of Exceltis Healthcare, has received national marketing authorization from the Spanish Agency of Medicines and Medical Devices (AEMPS) for the product.

RIZAPORT^® is a proprietary oral thin film formulation of rizatriptan for the treatment of acute migraines.  RIZAPORT® offers an innovative and potentially advantageous therapeutic alternative for many migraine patients, primarily patients who suffer from dysphagia or migraine-related nausea, due to its convenient dosing, facile intake due to the lack of need for water, and neutral flavor.

Following the approval of the manufacturing site transfer of RIZAPORT^® from the European contract manufacturer listed in the initial manufacturing site transfer application to IntelGenx’s GMP compliant facility in Montreal, Canada, this marketing authorization will enable IntelGenx’s marketing partner, Exceltis Healthcare, to commercialize the product in Spain.  The Company believes that recently reported results from a successful study, demonstrating that RIZAPORT® is bioequivalent to the European reference, Maxalt®-Lingua, will further support the site transfer application in Spain.

“This marketing authorization in Spain marks the achievement of a major milestone for our company, materially advancing RIZAPORT® toward becoming the first-ever commercialized VersaFilm™ product to be manufactured at our new state-of-the-art facility,” said Dr. Horst G. Zerbe, President and CEO of IntelGenx.

About RIZAPORT^® (RHB-103):

RIZAPORT^® is a proprietary oral thin film formulation of rizatriptan benzoate, a 5-HT1 receptor agonist and the active drug in Merck & Co.'s Maxalt^®.  A New Drug Application for RIZAPORT^® was resubmitted to the U.S. Food and Drug Administration in September 2017.

Rizatriptan is considered to be one of the most effective oral triptans, a class of molecules that constricts blood vessels in the brain to relieve swelling and other migraine symptoms. RIZAPORT^® is based on IntelGenx’s proprietary VersaFilm™ technology.  It dissolves rapidly and releases its active ingredient in the mouth, leading to efficient absorption of the drug through the gastrointestinal tract.  The administration method of the RIZAPORT^® oral soluble film, which does not require the patient to swallow a pill or consume water, along with its neutral flavor, presents a potentially attractive therapeutic alternative for migraine patients, specifically for patients who suffer from migraine-related nausea, estimated to be approximately 80% of the total migraine patient population and patients suffering from dysphagia (difficulty swallowing)¹.

Reference:

¹ Lipton RB, Buse DC, Saiers J, Fanning KM, Serrano D, Reed ML. (2013) Frequency and burden of headache-related nausea: results from the American Migraine Prevalence and Prevention (AMPP) study, Headache. 2013 Jan;53(1):93-103.

About IntelGenx:

Established in 2003, IntelGenx is a leading oral drug delivery company primarily focused on the development and manufacturing of innovative pharmaceutical oral films based on its proprietary VersaFilm™ technology platform.

IntelGenx’s highly skilled team provides comprehensive pharmaceuticals services to pharmaceutical partners, including R&D, analytical method development, clinical monitoring, IP and regulatory services.  IntelGenx’s state-of-the-art manufacturing facility, established for the VersaFilm™ technology platform, supports lab-scale to pilot and commercial-scale production, offering full service capabilities to its clients.  More information about the company can be found at www.intelgenx.com.

Forward Looking Statements:

This document may contain forward-looking information about IntelGenx’s operating results and business prospects that involve substantial risks and uncertainties. Statements that are not purely historical are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. These statements include, but are not limited to, statements about IntelGenx’s plans, objectives, expectations, strategies, intentions or other characterizations of future events or circumstances and are generally identified by the words "may," "expects," "anticipates," "intends," "plans," "believes," "seeks," "estimates," "could," "would," and similar expressions.  All forward looking statements are expressly qualified in their entirety by this cautionary statement. Because these forward-looking statements are subject to a number of risks and uncertainties, IntelGenx’s actual results could differ materially from those expressed or implied by these forward-looking statements.  Factors that could cause or contribute to such differences include, but are not limited to, those discussed under the heading "Risk Factors" in IntelGenx’s annual report on Form 10-K, filed with the United States Securities and Exchange Commission and available at www.sec.gov, and also filed with Canadian securities regulatory authorities at www.sedar.com. IntelGenx assumes no obligation to update any such forward-looking statements.

Each of the TSX Venture Exchange and OTCQX has neither approved nor disapproved the contents of this press release.  Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Source:  IntelGenx Technologies Corp.

For more information, please contact:


Stephen Kilmer

Investor Relations 

(514) 331-7440 ext 232

stephen@intelgenx.com

Or

Andre Godin, CPA, CA

Executive Vice-President and CFO

IntelGenx Corp.

(514) 331-7440 ext 203

andre@intelgenx.com

SAINT LAURENT, Quebec, Oct. 26, 2018 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. (TSXV:IGX) (OTCQX:IGXT) (the “Company” or “IntelGenx”) announces that in connection with its previously announced public offering (the “Offering”) of units of the Company (the “Units”) for aggregate gross proceeds of approximately US$12 million, Echelon Wealth Partners Inc. (“Echelon”), who acted as the Company’s exclusive placement agent in Canada in connection with the Offering, has exercised its option to place a further 903,610 Units pursuant to its over-allotment option (the “Over-Allotment Option”), resulting in additional gross proceeds to the Company of US$632,527.

Each Unit was issued at a price of US$0.70 and was comprised of one share of common stock (the “Offered Shares”) and one half of one warrant (a “Warrant”), each whole Warrant entitling the holder to purchase one share of common stock of the Company at an exercise price of US$1.00 per share. The Warrants are exercisable immediately and will expire on October 22, 2021.

The Units were distributed under a final prospectus supplement to the U.S. registration statement on Form S-3 (File No. 333-227498) which was declared effective on October 15, 2018 (the “Registration Statement”) and a final Canadian MJDS prospectus supplement to the Canadian MJDS short-form base shelf dated October 18, 2018 filed by the Company in connection with the Offering.

Including the net proceeds from the exercise of the Over-Allotment Option, the Company expects the aggregate net proceeds of the Offering to be approximately US$11 million. The Company intends to use the net proceeds from the Offering for its 2a Montelukast Study, its Tadalafil 505(b)(2) submission to the U.S. Food and Drug Administration, and working capital.

About IntelGenx:

Established in 2003, IntelGenx is a leading oral drug delivery company primarily focused on the development and manufacturing of innovative pharmaceutical oral films based on its proprietary VersaFilm™ technology platform.

IntelGenx' highly skilled team provides comprehensive pharmaceuticals services to pharmaceutical partners, including R&D, analytical method development, clinical monitoring, IP and regulatory services. IntelGenx' state-of-the-art manufacturing facility, established for the VersaFilm™ technology platform, supports lab-scale to pilot and commercial-scale production, offering full service capabilities to its clients. More information about the company can be found at www.intelgenx.com.

Forward Looking Information and Statements:

This document may contain forward-looking information or forward-looking statements within the meaning of applicable U.S. and Canadian securities laws. These statements are statements that are not purely historical and include, but are not limited to, statements about the use of the Offering proceeds, IntelGenx' plans, objectives, expectations, strategies, intentions or other characterizations of future events or circumstances and are generally identified by the words “may”, “expects”, “anticipates”, “intends”, “plans”, “believes”, “seeks”, “estimates”, “could”, “would”, and similar expressions. All forward looking statements are expressly qualified in their entirety by this cautionary statement. Because these forward-looking statements are subject to a number of risks and uncertainties, IntelGenx' actual results could differ materially from those expressed or implied by these forward looking statements.

Factors that could cause or contribute to such differences include, but are not limited to, those discussed under the heading “Risk Factors” in the Registration Statement and in IntelGenx' annual report on Form 10-K, filed with the United States Securities and Exchange Commission and available at www.sec.gov, and also filed with Canadian securities regulatory authorities and www.sedar.com. IntelGenx assumes no obligation to update any such forward-looking statements.

Although the Company believes that the expectations and assumptions on which Forward-Looking Information is based are reasonable, readers of this press release are cautioned not to rely unduly on this Forward-Looking Information since no assurance can be given that they will prove to be correct. The Company does not undertake any obligation to update or revise any Forward-Looking Information, whether as a result of events or circumstances occurring after the date of this press release, unless so required by legislation.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

No securities regulatory authority has either approved or disapproved of the contents of this press release. This press release does not constitute an offer to sell or a solicitation of an offer to buy any securities of the Company in any jurisdiction in which such offer or solicitation of sale would be unlawful.

For more information, please contact:


Stephen Kilmer

Investor Relations

(514) 331-7440 ext 232 

stephen@intelgenx.com 

OR

Andre Godin, CPA, CA

Executive Vice-President and CFO

IntelGenx Technologies Corp.

(514) 331-7440 ext 203

andre@intelgenx.com 

SAINT LAURENT, Quebec, Oct. 18, 2018 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. (TSX-V:IGX) (OTCQX:IGXT) (the “Company” or “IntelGenx”) announced today the pricing of an agency offering (the “Offering”) of 17,144,314 units (the “Units”) for gross proceeds of approximately US$12,000,000 million at a price of US$0.70 per Unit (the “Offering Price”). Each Unit will consist of one share of common stock of the Company (an “Offered Share”) and one half of one warrant (a “Warrant”) each whole Warrant to purchase one share of common stock of the Company at an exercise price of US$1.00 per share (a “Warrant Share”). The Warrants will be exercisable immediately and will expire on the third anniversary of the date of their issuance.

The Offering is made on a best efforts basis in the United States and the Canadian provinces of British Columbia, Alberta, Manitoba, Ontario and Québec. H.C. Wainwright & Co. (“Wainwright”) is acting as the exclusive agent for the Units offered in the United States. Echelon Wealth Partners Inc. (“Echelon”) is acting as the exclusive placement agent for the Units offered in Canada.

The closing of the Offering is expected to occur on or about October 22, 2018.

The Company has granted Echelon an over-allotment option exercisable, in whole or in part, at the sole discretion of Echelon, at any time prior to 5:00 p.m. (Montreal time) on the date that is the 30th day after the closing of the Offering, to purchase shares of common stock of the Company and/or Warrants in an amount representing up to an additional 15% of the number of Units sold pursuant to the Offering, at the Offering Price to cover over-allocations, if any, and for market stabilization purposes.

The Company intends to use the net proceeds of the Offering for its 2a Montelukast study, Tadalafil 505(b)(2) submission to U.S. Food and Drug Administration, and working capital.

The Company has applied to the TSX Venture Exchange (“TSXV”) for approval of the listing of the Offered Shares and the Warrant Shares. The approval is subject to fulfillment by the Company of customary conditions of TSXV. There is no established trading market for the Warrants and IntelGenx does not expect a market to develop. IntelGenx does not intend to list the Warrants on any national securities exchange or any other nationally recognized trading system

The Company intends to file a final prospectus supplement (the “U.S. Supplement”) to the U.S. registration statement on Form S-3 (File No. 333-227498) which was declared effective on October 15, 2018 (the “Registration Statement”) and a final Canadian MJDS prospectus supplement (the “Canadian Supplement”) to the Canadian MJDS short-form base shelf prospectus dated October 15, 2018 (the “MJDS Prospectus”) with respect to the Offering today.

Before investing, you should read the Canadian Supplement, the U.S. Supplement, the MJDS Prospectus and the Registration Statement as well as other documents the Company has filed or will file later today with the United States Securities and Exchange Commission (the “SEC”) and the Canadian securities regulators for more complete information about the Company and this offering. Copies of the Canadian Supplement and the MJDS Prospectus are available under the Corporation’s profile at www.sedar.com and copies of the U.S. Supplement and the Registration Statement can be obtained from the SEC’s website at www.sec.gov.

Copies of the U.S. Supplement, when filed, and the Registration Statement may also be obtained from H.C. Wainwright & Co., LLC, 430 Park Avenue, 3rd Floor, New York, NY 10022, by calling (646) 975-6996 or by emailing placements@hcwco.com, and copies of the Canadian Supplement and the MJDS Prospectus may also be obtained from Echelon Wealth Partners Inc., 1 Adelaide Street East, Suite 2100, Toronto, ON M5C 2V9, by calling (416) 479-7370 or emailing ecm@echelonpartners.com.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of, Units, Warrants or shares of common stock of the Company in any state or province in which such offer, solicitation or sale would be unlawful, prior to registration or qualification under the securities laws of any such state, province, or other jurisdiction.   

About IntelGenx

Established in 2003, IntelGenx is a leading oral drug delivery company primarily focused on the development and manufacturing of innovative pharmaceutical oral films based on its proprietary VersaFilm™ technology platform.

IntelGenx' highly skilled team provides comprehensive pharmaceuticals services to pharmaceutical partners, including R&D, analytical method development, clinical monitoring, IP and regulatory services. IntelGenx' state-of-the-art manufacturing facility, established for the VersaFilm™ technology platform, supports lab-scale to pilot and commercial-scale production, offering full service capabilities to its clients. More information about the Company can be found at www.intelgenx.com.

Forward-Looking Information and Statements

This document may contain forward-looking information or forward-looking statements within the meaning of applicable U.S. and Canadian securities laws. These statements are statements that are not purely historical. All forward-looking statements are expressly qualified in their entirety by this cautionary statement. These statements are statements that are not purely historical and include, but are not limited to, statements about the completion of the Offering, the use of the Offering proceeds, IntelGenx's plans, objectives, expectations, strategies, intentions or other characterizations of future events or circumstances and are generally identified by the words “may”, “expects”, “anticipates”, “intends”, “plans”, “believes”, “seeks”, “estimates”, “could”, “would”, and similar expressions. These forward-looking statements include statements regarding the terms of the Offering, the use of proceeds, the listing of the Offered Shares and Warrant Shares on the TSXV, the declaration of the effectiveness of the Registration Statement, and the timing for and the closing of the Offering. All forward looking statements are expressly qualified in their entirety by this cautionary statement. Because these forward-looking statements are subject to a number of risks and uncertainties, IntelGenx's actual results could differ materially from those expressed or implied by these forward looking statements. Factors that could cause or contribute to such differences include, but are not limited to, failure to raise the minimum gross proceeds, those discussed under the heading “Risk Factors” in the Registration Statement and IntelGenx's annual report on Form 10-K, filed with the United States Securities and Exchange Commission and available at www.sec.gov, and also filed with Canadian securities regulatory authorities and www.sedar.com. Although the Company believes that the expectations and assumptions on which Forward-Looking Information is based are reasonable, readers of this press release are cautioned not to rely unduly on this Forward-Looking Information since no assurance can be given that they will prove to be correct. The Company does not undertake any obligation to update or revise any Forward-Looking Information, whether as a result of events or circumstances occurring after the date of this press release, unless so required by legislation.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

No securities regulatory authority has either approved or disapproved of the contents of this press release. This press release does not constitute an offer to sell or a solicitation of an offer to buy any securities of the Company in any jurisdiction in which such offer or solicitation of sale would be unlawful.

For more information, please contact:

Stephen Kilmer
Investor Relations
(514) 331-7440 ext 232
stephen@intelgenx.com

OR

Andre Godin, CPA, CA
Executive Vice-President and CFO
IntelGenx Technologies Corp.
(514) 331-7440 ext 203
andre@intelgenx.com

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

SAINT LAURENT, Quebec, Oct. 17, 2018 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. (TSX-V: IGX) (OTCQX: IGXT) (the “Company” or “IntelGenx”) is pleased to announce that, since September 15, 2018, it has received proceeds of US$1,634,294 as a result of the exercise of 2,894,606 previously issued common share purchase warrants (the “Warrants”).

The exercised Warrants were issued in connection with the Company’s public offering of units completed in December 2013, and were set to expire on December 15, 2018.  The exercise price of the Warrants was $0.5646.  No commissions or placement fees have been paid related to the funds received from these exercised Warrants.  Proceeds will be used for general corporate purposes.

Following the exercise of these Warrants, IntelGenx continues to have an aggregate of 2,730,371 share purchase warrants outstanding, of which 76,296 were issued under the December 2013 public offering and 2,654,075 were issued under the Company’s May 2018 private placement.

About IntelGenx:

Established in 2003, IntelGenx is a leading oral drug delivery company primarily focused on the development and manufacturing of innovative pharmaceutical oral films based on its proprietary VersaFilm™ technology platform.

IntelGenx' highly skilled team provides comprehensive pharmaceuticals services to pharmaceutical partners, including R&D, analytical method development, clinical monitoring, IP and regulatory services.  IntelGenx' state-of-the-art manufacturing facility, established for the VersaFilm™ technology platform, supports lab-scale to pilot and commercial-scale production, offering full service capabilities to its clients.  More information about the company can be found at www.intelgenx.com.

Forward Looking Statements:

This document may contain forward-looking information about IntelGenx's operating results and business prospects that involve substantial risks and uncertainties. Statements that are not purely historical are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. These statements include, but are not limited to, statements about IntelGenx' plans, objectives, expectations, strategies, intentions or other characterizations of future events or circumstances and are generally identified by the words "may," "expects," "anticipates," "intends," "plans," "believes," "seeks," "estimates," "could," "would," and similar expressions.  All forward looking statements are expressly qualified in their entirety by this cautionary statement. Because these forward-looking statements are subject to a number of risks and uncertainties, IntelGenx' actual results could differ materially from those expressed or implied by these forward-looking statements.  Factors that could cause or contribute to such differences include, but are not limited to, those discussed under the heading "Risk Factors" in IntelGenx' annual report on Form 10-K, filed with the United States Securities and Exchange Commission and available at www.sec.gov, and also filed with Canadian securities regulatory authorities at www.sedar.com. IntelGenx assumes no obligation to update any such forward-looking statements.

Each of the TSX Venture Exchange and OTCQX has neither approved nor disapproved the contents of this press release.  Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Source:  IntelGenx Technologies Corp.

For more information, please contact:


Stephen Kilmer

Investor Relations 

(514) 331-7440 ext 232

stephen@intelgenx.com

Or

Andre Godin, CPA, CA

Executive Vice-President and CFO

IntelGenx Corp.

(514) 331-7440 ext 203

andre@intelgenx.com

SAINT LAURENT, Quebec, Oct. 04, 2018 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSX-V: IGX) (OTCQX: IGXT) (the “Company” or “IntelGenx”) today announced that an Abbreviated New Drug Application (“ANDA”) for a generic buccal film product has been submitted to the U.S. Food and Drug Administration (“FDA”) by its partner, Insud Pharma (formerly Chemo Group).  

“The filing of an ANDA for this product, one of several products being co-developed in a partnership between IntelGenx and Insud Pharma, marks the achievement of a major milestone and serves to help demonstrate the strength of our collaboration,” commented Dr. Horst Zerbe, IntelGenx’s President and CEO.

Under the terms of the agreement with Insud Pharma, Insud Pharma has obtained certain exclusive rights to market and sell the IntelGenx generic buccal film product (which comprises a novel formulation based on IntelGenx’s VersaFilm™ technology) in exchange for upfront and milestone payments, together with a share of the profits of commercialization once the product is authorised.

About Insud Pharma:

With more than 40 years of experience, Insud Pharma (before Chemo Group) has become an established, global group in the pharmaceutical industry, with continuous growth and diversification.

Insud Pharma operates across the entire pharmaceutical value chain, delivering specialized expertise in scientific research, development, manufacturing, sales and marketing of a wide range of value-adding APIs, finished dosage forms (FDFs) and branded pharmaceuticals, for human and animal health.

While the main offices are located in Spain, Switzerland and Argentina, Insud Pharma has a truly global footprint and has built a broad and balanced manufacturing and commercial network across Europe, North and South America, Asia and Africa, to address global opportunities and customers’ needs in all major pharmaceutical markets.

Insud Pharma’s activity is organized in three synergistic business areas: Industrial, Branded and Biotech, with over 6,000 professionals in more than 40 countries, 17 state-of-the-art facilities, more than 15 specialized R&D centers and more than 40 pharmaceutical affiliates, serving 1,150 customers in 96 countries around the world.

About IntelGenx:

Established in 2003, IntelGenx is a leading oral drug delivery company primarily focused on the development and manufacturing of innovative pharmaceutical oral films based on its proprietary VersaFilm™ technology platform.

IntelGenx’s highly skilled team provides comprehensive pharmaceuticals services to pharmaceutical partners, including R&D, analytical method development, clinical monitoring, IP and regulatory services. IntelGenx’s state-of-the-art manufacturing facility, established for the VersaFilm™ technology platform, supports lab-scale to pilot and commercial-scale production, offering full service capabilities to its clients. More information about the company can be found at www.intelgenx.com.

Forward Looking Statements:

This document may contain forward-looking information about IntelGenx’s operating results and business prospects that involve substantial risks and uncertainties. Statements that are not purely historical are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. These statements include, but are not limited to, statements about IntelGenx’s plans, objectives, expectations, strategies, intentions or other characterizations of future events or circumstances and are generally identified by the words "may," "expects," "anticipates," "intends," "plans," "believes," "seeks," "estimates," "could," "would," and similar expressions. All forward looking statements are expressly qualified in their entirety by this cautionary statement. Because these forward-looking statements are subject to a number of risks and uncertainties, IntelGenx’s actual results could differ materially from those expressed or implied by these forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those discussed under the heading "Risk Factors" in IntelGenx’s annual report on Form 10-K, filed with the United States Securities and Exchange Commission and available at www.sec.gov, and also filed with Canadian securities regulatory authorities at www.sedar.com. IntelGenx assumes no obligation to update any such forward-looking statements.

Each of the TSX Venture Exchange and OTCQX has neither approved nor disapproved the contents of this press release.  Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Source:  IntelGenx Technologies Corp. 

For more information, please contact:


Stephen Kilmer

Investor Relations 

(514) 331-7440 ext 232

stephen@intelgenx.com

Or

Andre Godin, CPA, CA

Executive Vice-President and CFO

IntelGenx Corp.

(514) 331-7440 ext 203

andre@intelgenx.com

SAINT LAURENT, Quebec, Sept. 25, 2018 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSX-V: IGX) (OTCQX: IGXT) (the “Company” or “IntelGenx”) today announced that patient recruitment will commence for the Phase 2a study with Montelukast VersaFilm™ in patients with mild to moderate Alzheimer’s Disease (“AD”). Two research sites (the Centre for Memory and Aging in Toronto, ON and True North Clinical Research in Halifax, NS) are being activated and will be open for patient enrolment as of September 26, 2018, with additional sites planning to initiate patient screening in the near future.

This randomized, double-blind, placebo controlled Phase 2a proof of concept study will enroll approximately 70 subjects with mild to moderate AD across eight Canadian research sites. The primary study objectives will be to evaluate the safety, feasibility, tolerability, and efficacy of Montelukast buccal film following daily dosing for 26 weeks.

“As treatment options are limited, and with no approved drugs being disease modifying, there is no question that AD remains an area of significant unmet medical need,” said Dr. Horst G. Zerbe, President and CEO of IntelGenx. “Accordingly, if proven to be effective, Montelukast has the potential to be a truly impactful in the treatment of this terrible disease.”

About Montelukast VersaFilm™:

Montelukast is a leukotriene receptor antagonist that was approved by the U.S. Food and Drug Administration in 1997 for the treatment of asthma and seasonal allergic rhinitis. Montelukast is a CysLT1 antagonist; it blocks the action of leukotriene D4 (and secondary ligands LTC4 and LTE4) on the cysteinyl leukotriene receptor CysLT1 in the lungs and bronchial tubes by binding to it. This reduces the bronchoconstriction otherwise caused by the leukotriene and results in less inflammation. 

IntelGenx is working to repurpose Montelukast as a therapeutic to treat neurodegenerative diseases by re-formulating the drug into an oral film-based product. IntelGenx ' proprietary VersaFilm™ technology is especially suited for special needs patient populations, and the Montelukast VersaFilm™ product therefore offers many distinct advantages over tablets for Alzheimer’s Disease patients, including the avoidance and minimization of first-pass-effects, ease of administration, improved API bioavailability, lower dosing and toxicity, better acceptability and improved compliance.

In a recent Phase 1 study, IntelGenx demonstrated that an oral film formulation of Montelukast is safe and tolerable in healthy subjects, reduces the first-pass-effect and has a 52% higher bioavailability compared to the regular Montelukast tablet, demonstrating a clear advantage of delivering Montelukast via film. IntelGenx's oral film also crossed the blood-brain barrier, an essential feature for treating degenerative brain diseases.

About IntelGenx:

Established in 2003, IntelGenx is a leading oral drug delivery company primarily focused on the development and manufacturing of innovative pharmaceutical oral films based on its proprietary VersaFilm™ technology platform.

IntelGenx’s highly skilled team provides comprehensive pharmaceuticals services to pharmaceutical partners, including R&D, analytical method development, clinical monitoring, IP and regulatory services. IntelGenx’s state-of-the-art manufacturing facility, established for the VersaFilm™ technology platform, supports lab-scale to pilot and commercial-scale production, offering full service capabilities to its clients. More information about the company can be found at www.intelgenx.com.

Forward Looking Statements:

This document may contain forward-looking information about IntelGenx’s operating results and business prospects that involve substantial risks and uncertainties. Statements that are not purely historical are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. These statements include, but are not limited to, statements about IntelGenx’s plans, objectives, expectations, strategies, intentions or other characterizations of future events or circumstances and are generally identified by the words "may," "expects," "anticipates," "intends," "plans," "believes," "seeks," "estimates," "could," "would," and similar expressions. All forward looking statements are expressly qualified in their entirety by this cautionary statement. Because these forward-looking statements are subject to a number of risks and uncertainties, IntelGenx’s actual results could differ materially from those expressed or implied by these forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those discussed under the heading "Risk Factors" in IntelGenx’s annual report on Form 10-K, filed with the United States Securities and Exchange Commission and available at www.sec.gov, and also filed with Canadian securities regulatory authorities at www.sedar.com. IntelGenx assumes no obligation to update any such forward-looking statements.

Each of the TSX Venture Exchange and OTCQX has neither approved nor disapproved the contents of this press release. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Source: IntelGenx Technologies Corp.

For more information, please contact:


Stephen Kilmer

Investor Relations 

(514) 331-7440 ext 232

stephen@intelgenx.com

Or

Andre Godin, CPA, CA

Executive Vice-President and CFO

IntelGenx Corp.

(514) 331-7440 ext 203

andre@intelgenx.com

SAINT LAURENT, Quebec, Sept. 24, 2018 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSX-V: IGX) (OTCQX: IGXT) (the “Company” or “IntelGenx”) today announced successful results from a bioequivalence study for RIZAPORT^®, its proprietary anti-migraine VersaFilm™ product. The study results demonstrated RIZAORT^® is bioequivalent to the U.S. reference, Maxalt^®-MTL, and the European reference, Maxalt^®-Lingua. 

RIZAPORT^® is a proprietary oral thin-film formulation of rizatriptan for the treatment of acute migraines. RIZAPORT^® offers an innovative and potentially advantageous therapeutic alternative for many migraine patients, primarily patients who suffer from dysphagia or migraine-related nausea, due to its convenient dosing, facile intake due to the lack of need for water, and neutral flavor.

The bioequivalence study was a single-dose, randomized, open-label, three-way crossover, pivotal, comparative bioavailability study of RIZAPORT^® 10 mg, Maxalt^®-MLT 10 mg orally disintegrating tablets and Maxalt^®-Lingua 10 mg oro-dispersible tablets in 30 healthy volunteers. The study was conducted under the direction of Biopharma Services in Toronto, ON. 

The bioequivalence study is expected to support the submission of the additional information related to the transfer of manufacturing to IntelGenx’ GMP compliant site required by the U.S. Food and Drug Administration ("FDA") to allow for a full review of the Company’s 505(b)(2) New Drug Application ("NDA") resubmission for RIZAPORT^®. The study will also be used to support applications to transfer the manufacturing of RIZAPORT^® from the European contract manufacturer listed in the initial application to IntelGenx’ site. Additionally, it will be used to support applications in additional European countries.

“This successful bioequivalence study helps pave the way for RIZAPORT^®, once approved, to be the first commercialized VersaFilm™product to be manufactured at our new state-of-the-art facility,” said Dr. Horst G. Zerbe, President and CEO of IntelGenx.

“A few years ago, we made the strategic decision to transform IntelGenx from a development company that relied on royalty and license revenues from a limited product portfolio into a full-service, global leader of innovative pharmaceutical oral film development and manufacturing," continued Dr. Zerbe. "While that decision temporarily impacted on the Company’s profitability due to the need to make significant new investments in plant and people, we firmly believed that we had an opportunity to build a much stronger business – one able to drive significant and sustainable growth over both the mid- and long-terms. In many ways, anticipated approvals to manufacture RIZAPORT^® at IntelGenx’ site will serve to help validate that choice. We look forward to updating all of our stakeholders as we progress.” 

About RIZAPORT^® (RHB-103):

RIZAPORT^® is a proprietary oral thin film formulation of rizatriptan benzoate, a 5-HT1 receptor agonist and the active drug in Merck & Co.'s Maxalt^®. RIZAPORT^® 5 mg and 10 mg were approved for marketing in Germany in October 2015 and in Luxembourg in April 2017 under the European Decentralized Procedure. A New Drug Application for RIZAPORT^® was resubmitted to the FDA in October 2017.

Rizatriptan is considered to be one of the most effective oral triptans, a class of molecules that constricts blood vessels in the brain to relieve swelling and other migraine symptoms. RIZAPORT^® is based on IntelGenx' proprietary VersaFilm™ technology. It dissolves rapidly and releases its active ingredient in the mouth, leading to efficient absorption of the drug through the gastrointestinal tract. The administration method of the RIZAPORT^® oral soluble film, which does not require the patient to swallow a pill or consume water, along with its neutral flavor, presents a potentially attractive therapeutic alternative for migraine patients, specifically for patients who suffer from migraine-related nausea, estimated to be approximately 80% of the total migraine patient population and patients suffering from dysphagia (difficulty swallowing)¹.

Reference:

¹ Lipton RB, Buse DC, Saiers J, Fanning KM, Serrano D, Reed ML. (2013) Frequency and burden of headache-related nausea: results from the American Migraine Prevalence and Prevention (AMPP) study, Headache. 2013 Jan;53(1):93-103.

About IntelGenx:

Established in 2003, IntelGenx is a leading oral drug delivery company primarily focused on the development and manufacturing of innovative pharmaceutical oral films based on its proprietary VersaFilm™ technology platform.

IntelGenx' highly skilled team provides comprehensive pharmaceuticals services to pharmaceutical partners, including R&D, analytical method development, clinical monitoring, IP and regulatory services. IntelGenx' state-of-the-art manufacturing facility, established for the VersaFilm™ technology platform, supports lab-scale to pilot and commercial-scale production, offering full service capabilities to its clients. More information about the company can be found at www.intelgenx.com.

Forward Looking Statements:

This document may contain forward-looking information about IntelGenx' operating results and business prospects that involve substantial risks and uncertainties. Statements that are not purely historical are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. These statements include, but are not limited to, statements about IntelGenx' plans, objectives, expectations, strategies, intentions or other characterizations of future events or circumstances and are generally identified by the words "may," "expects," "anticipates," "intends," "plans," "believes," "seeks," "estimates," "could," "would," and similar expressions. All forward looking statements are expressly qualified in their entirety by this cautionary statement. Because these forward-looking statements are subject to a number of risks and uncertainties, IntelGenx' actual results could differ materially from those expressed or implied by these forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those discussed under the heading "Risk Factors" in IntelGenx' annual report on Form 10-K, filed with the United States Securities and Exchange Commission and available at www.sec.gov, and also filed with Canadian securities regulatory authorities at www.sedar.com. IntelGenx assumes no obligation to update any such forward-looking statements.

Each of the TSX Venture Exchange and OTCQX has neither approved nor disapproved the contents of this press release. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Source: IntelGenx Technologies Corp.

For more information, please contact:


Stephen Kilmer

Investor Relations 

(514) 331-7440 ext 232

stephen@intelgenx.com

Or

Andre Godin, CPA, CA

Executive Vice-President and CFO

IntelGenx Corp.

(514) 331-7440 ext 203

andre@intelgenx.com